In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5451-5455

  Tsunoda, Takuya ^a   Tanimura, Hiroshi ^a   Hotta, Tsukasa ^a   Tani, Masaji ^a   Iwahashi, Makoto ^a   Tanaka, Hajime ^a   Matsuda, Kenji ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colon cancer; CPT 11; Gastric cancer; MTT assay; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; TETRAZOLIUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; COLORECTAL CANCER; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; STOMACH NEOPLASMS;

EID: 0033368084     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Wall ME, Wani MC, Cook CE, Campbell HF and Levine SG: Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 88: 3888-3890, 1966.
2. Creemers GJ, Lund B and Verweij J: Topoisomerase I inhibitors: topotecan nd irinotecan. Cancer Treat Rev 20: 73-96, 1994.
3. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993.
4. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sasaki Y, Oguro M, Ito Y, Morishima Y, Yokomaku S and Ota K: An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912, 1990.
5. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K and Takada M: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
6. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S and Taguchi T: A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20, 1992.
7. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T and Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913, 1993.
8. Takeuchi S, Takamizawa H, Takeda Y, Ogawa T, Tamaya T, Noda K, Sugawa T, Sekiba K, Yakushiji M and Taguchi T: Clinical study of CPT-11, camptothecin derivative, on gynecological, malignancy (Abstract 617). Proc Am Soc Clin Oncol 10: 189, 1991.
9. Tsuji K, Kaneda N, Kado K, Yokokura T, Yoshimoto T and Tsuru D: CPT-11 converting enzyme from rat serum: purification and some properties. J pharmacobiol Dyn 14: 341-349, 1991.
10. Carmichael J, Mitchell JB, Degraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E and Minna JD: Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540-547, 1985.
11. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1083.
12. Twentyman PR, Fox NE and Rees JKH: Chemosensitivity testing of fresh leukaemia cells using the MTT calorimetric assay. Br J Haematol 71: 19-24, 1989.
13. Campling BJ, Pym J, Baker HM, Cole SPC and Lam YM: Chemosensitivity testing of small cell lung cancer using the MTT assay. Br J Cancer 63: 75-83, 1991.
14. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, Noguchi K, Tamai M, Hotta T and Arii K: Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer 27: 1258-1263, 1991.
15. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M and Iwakura S: Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 66: 794-799, 1992.
16. Yamaue H, Tanimura H, Nakamori M, Noguchi K, Iwahashi M, Tani M, Hotta T, Murakami K and Ishimoto K: Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Dis Colon Rectum 39: 416-422, 1996.
17. Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tamai M, Noguchi K, Mizobata S and Arii K: Interleukin 4 inhibits LAK and initial phase TIL activity via interleukin 2 receptor. Int J Oncol 7: 1117-1121, 1995.
18. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selawry OS: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
19. Moertel CG, Schutt AJ, Reitemeier RJ and Hahn RG: Phase II study of Camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
20. Yokokura T, Furuta T, Sawada S, Sugino E, Mutai M and Miyasaka T: Antitumor activity of newly synthesized lactone ring-crossed and water-soluble camptothecin derivative in mice. Proc Jpn Cancer Assoc, 43th Ann Meeting (abstr), 261, 1984.
21. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin against murine tumor. Cancer Res 47: 5944-5947, 1987.
22. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, Tamai M, Noguchi K, Mizobata S, Arii K and Terasawa H: Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J Surg Res 66: 31-35, 1996.
23. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, Tamai M, Noguchi K, Mizobata S, Arii K and Terasawa H: Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Oncology 54: 153-157, 1997.
24. Tsuruo T, Matsuzaki T, Matsusita M, Saito H and Yokokura T: Antitumor effect of CPT-11, a new derivative of camptothecin against pleiotropic drug- resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71-74, 1988.
25. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M and Saijo N: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56: 789-793, 1996.
26. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K and Kishimoto S: CPT-11 in combination with cisplatin foradvanced non-small-cell lung cancer. J Clin Oncol 10: 1775-1780, 1992.